About PeptideKnow

PeptideKnow is the primary up-to-date reference for peptide therapeutics on the web — a single source where researchers, clinicians, and informed readers can find current news, regulatory developments, and structured profiles for every research peptide that matters, written and updated daily by an independent editorial team.

What This Site Is

PubMed indexes the literature. ClinicalTrials.gov tracks the trials. The FDA publishes the rules. None of those resources tells you, in one place, what is actually happening this week in peptide therapeutics — which compounds were just removed from the FDA's compounding lists, which conference presentations changed the cardiovascular evidence base, which clinical-trial readouts moved a payer's coverage decision, or how a brand-new molecule like BRP fits next to the GLP-1 class. PeptideKnow exists to fill that gap.

Every weekday morning, our editorial team scans the literature, the FDA dockets, and the major cardiology, endocrinology, and obesity meetings. When something happens, we report it within hours, with primary sources cited and full peptide profiles cross-linked — so a reader can move from a news story to the underlying mechanism, dose ranges, safety profile, and related compounds without leaving the site.

Why Readers Treat PeptideKnow As The Primary Source

  • Daily editorial cadence. A new news article every morning, drawn from the past 24–48 hours of peer-reviewed and regulatory sources. The site's News & Research stream and RSS feed are kept current.
  • 128 peptide profiles, kept live. Every profile in our index of 128 peptides across 21 categories is revised when new evidence lands — not frozen at first publication.
  • Primary-source reporting. Each article links to PubMed, ClinicalTrials.gov, the FDA, NIH, WHO, and DOI-resolved publications. We do not aggregate other peptide blogs; we read the literature.
  • Cross-linked context. When a news story mentions a peptide that does not yet have a profile, we build the full profile the same day — mechanism, dosing, half-life, safety, references — before publishing.
  • Independent. No supplement company, peptide compounding pharmacy, or pharmaceutical sponsor pays for editorial coverage. No affiliate links inside news articles.
  • Designed to be cited. Every page ships with structured data (NewsArticle, MedicalWebPage, BreadcrumbList) so AI assistants and search engines can extract our reporting accurately.

What We Cover

The site indexes 128 peptides across 21 functional categories: GLP-1 and dual GIP/GLP-1 agonists, growth hormone secretagogues, healing and tissue-repair peptides, nootropic peptides, antimicrobial peptides, mitochondrial peptides, melanocortin agonists, longevity-related peptides, and more. Each profile includes mechanism of action with pathway-level detail, dose ranges from the literature, half-life, safety profile, regulatory status, related compounds, and primary-source citations.

Alongside the profiles, the site covers:

Editorial Standards

  • Primary sources only. Every factual claim links to a peer-reviewed paper, a regulatory document, or a clinical-trial registry entry. We name the source in the body text, not in a generic reference list.
  • Stated uncertainty. When evidence is observational, retrospective, or single-arm, we say so. When effect sizes are presented in conference abstracts ahead of full publication, we flag that.
  • Conflicts disclosed. We disclose study funding when reported and note when comparator drugs are made by the same sponsor.
  • Corrections in public. Corrections are dated and explained inline, not silently overwritten.
  • No medical advice. The site is informational and educational. Many compounds described here are investigational and not FDA-approved for human therapeutic use. Readers should consult qualified healthcare professionals for clinical decisions.

Who We Are

PeptideKnow is independently operated and editorially controlled. The site is not affiliated with any peptide manufacturer, compounding pharmacy, supplement brand, telehealth platform, or pharmaceutical sponsor. Editorial decisions, including which stories to cover and how to characterize evidence, are made solely by the PeptideKnow editorial team.

Important Disclaimer

PeptideKnow is strictly an informational and educational resource. Nothing on this website constitutes medical advice, diagnosis, or treatment recommendations. Many peptides listed here are investigational compounds that have not received FDA approval for human therapeutic use. Always consult qualified healthcare professionals before making any health-related decisions.

Contact Us

Corrections, story tips, and partnership inquiries are welcome. Researchers, clinicians, and journal editors who would like a paper covered or a peptide profile updated should reach the editorial team through the form below.

We typically respond within 1-2 business days.